Page 203 - Genentech News Today

“I don’t see any reason why centers should not be using tenecteplase,” Bijoy Menon says.

Sanofi announces change in R&D leadership Paris, February 13, 2023. Sanofi announced today that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside

        As part of February’s Age-related Macular Degeneration (AMD) and Low Vision Awareness Month, the Ohio Affiliate of Prevent Blindness, is offering free resources to the public to help educate and empower individuals and their care partners to make informed decisio

Major players in the arthritis monoclonal antibodies market are Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc., Amgen Inc., Genentech, GSK,...

/PRNewswire/ -- The patient switch territory is evolving as more agents become available. Spherixs RealWorld Dynamix™ report allows for an inside look into...

A fine midwinter tradition in Washington, D.C., is the parade of press releases from K Street announcing which former senators and congressmen have joined which lobbying firms.

Island Pharmaceuticals Ltd (ASX:ILA) CEO and managing director David Foster believes in the vital role of the biotech industry in harnessing science to...

Basel, 10 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Roche Long Term Foundation acquired 540'000 Roche bearer shares at the price determined via an accelerated book building

SOUTH SAN FRANCISCO (dpa-AFX) - Genentech's vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion or RVO, as per new data from two global Phase III studies

Potentially registrational VB-C-04 trial in the U.S. expected to initiate 4Q 2023The GOG Foundation, Inc. (GOG) is a U.S. based not-for-profit organization...